MONOAMINERGIC ENZYMES IN SCHIZOPHRENIA
精神分裂症中的单胺能酶
基本信息
- 批准号:2675431
- 负责人:
- 金额:$ 10.72万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1996
- 资助国家:美国
- 起止时间:1996-09-15 至 2000-04-30
- 项目状态:已结题
- 来源:
- 关键词:amine oxidase (flavin) aromatic L aminoacid decarboxylase brain mapping cerebral cortex corpus striatum dopamine beta monooxygenase human tissue locus coeruleus neurochemistry nucleus accumbens postmortem protein isoforms schizophrenia tryptophan 5 monooxygenase tyrosine 3 monooxygenase western blottings
项目摘要
DESCRIPTION: (Adapted from applicant's abstract) Tyrosine hydroxylase
(TyrOH) and tryptophan hydroxylase (TrpOH) catalyze the rate-limiting steps
in catecholamine (dopamine and norepinephrine) and serotonin biosynthesis,
respectively. Alterations in each of these systems have been implicated in
mental disorders and, in particular schizophrenia. TyrOH is highly
regulated--by protein phosphorylation in the short-term and by
transcriptional control in the long-term. Alternative splicing (which
occurs exclusively in monkeys and humans) produces multiple TyrOH isoforms
having different phosphorylation sites, such that changes in RNA splicing or
in relative mRNA/protein turnover rates among isoforms could represent an
additional level of regulation. By contrast, despite the close evolutionary
and functional similarities between TrpOH and TyrOH, very little is known
about the regulation of TrpOH. Moreover, even less is known regarding the
status of these enzymes in mental disorders.
Postmortem human brain tissue will be analyzed using quantitative blot
immunolabeling techniques. TyrOH and TrpOH protein levels, as well as the
relative abundances of TyrOH isoforms, will be determined in several brain
regions. Depending upon the brain region/monoamine system being studied,
DOPA decarboxylase (which catalyzes the second step in catecholamine and
serotonin biosynthesis) and dopamine beta-hydroxylase (which converts
dopamine to norepinephrine) protein levels will also be determined. The
primary study groups will be (a) suicide/sudden death victims having
diagnoses of schizophrenia from psychiatric autopsy and (b) age-matched,
sudden-death control subjects having no axis 1 mental disorder. Additional
toxicological and neuropathological screening criteria will be applied to
all cases, and samples will be processed in a blind, matched-pairs design
for the neurochemical analyses. Coordination of experimental procedures
with ongoing studies of major depressives from the same collection of brains
will enable direct comparisons between the disorders. An independent cohort
of schizophrenics and age-matched controls (and bipolar affective disorder
comparison group) will be used for replicating effects in selected brain
regions.
描述:(改编自申请人摘要)酪氨酸羟化酶
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
JOHN W HAYCOCK其他文献
JOHN W HAYCOCK的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}